Further evidence of the cardiovascular benefits of SGLT2 inhibitors in diabetes has emerged showing a protective effect of canagliflozin against heart failure, especially in patients with pre-existing disease. While CANVAS trial results from more than 10,000 patients have already shown a reduced risk of composite cardiovascular outcomes with canagliflozin (Invokana), a new analysis by Australian ...
Canagliflozin shows clear benefit in heart failure CANVAS
By Michael Woodhead
14 Mar 2018